检索结果-南通市图书馆

Oral Manifestations of Chloroquine and Hydroxychloroquine: Differential Diagnoses

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Effect of Familiarization on the Reliability of Isokinetic Assessment in Breast Cancer Survivors

Open Journal of Stomatology（口腔学期刊） 2020年第11期

来源：评论

学校读者我要写书评

暂无评论

Journal of Science in Sport and Exercise 2020年第3期2卷 220-225页

作者： filipe D.de Lima Claudio L.Battaglini Sandro N.chaves Lucas Ugliara Jonathan Sarandy Martim Bottaro College of Health Sciences University of BrasiliaBrasiliaBrazil College of Education and Health Sciences University Center of BrasiliaBrasiliaBrazil Department of Exercise and Sport Science and Lineberger Comprehensive Cancer Center University of North Carolina at Chapel HillChapel HillUSA College of Physical Education University of BrasiliaBrasiliaDFBrazil Integrated College IESGO FormosaBrazil

Purpose To determine the amount of familiarization sessions required by breast cancer survivors to achieve a reliable meas-urement of muscle function assessed using isokinetic *** Twenty-six breast cancer survivors performed three isokinetic knee extension tests separated by,at least,48 *** isokinetic testing protocol included one warm-up set of 10 submaximal knee extensions at 120°/s,followed by two sets of four maximal knee extensions at 60°/s,with 2-min rest interval between *** torque(PT),time to peak torque(TPT),angle of peak torque(APT),and average power(AP)of each trial was used for the assessment of testing *** change in the mean,typical error,coefficient of variation and intraclass correlation coefficients(ICC2.1)were calculated to determine test-retest *** For PT,change in mean was lower between trials 2 and 3 than between trials 1 and 2(4.18% and 13.18%,respec-tively),and ICC was greater between trials 2 and 3 than between trials 1 and 2(0.962 and 0.818,respectively).For TPT and APT,ICC was clinically acceptable only between trials 2 and 3(0.757 and 0.803,respectively).For AP,change in mean was clinically acceptable between trials 2 and 3(9.84%),while ICC met acceptable reliability between both,trials 1 and 2 and,trials 2 and 3(0.756 and 0.891,respectively).Conclusion At least one familiarization session is adequate to achieve reliable measurements of muscle function using isokinetic dynamometry,while avoiding the impact of learning effect of the measurements in breast cancer survivors.

关键词： Muscle strength Breast cancer Isokinetic testing Resistance exercise Motor learning effect

Scalp Melanoma Treated with Ipilimumab in Elderly Patient： A Complete Response to Treatment--Case Report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Pharmacy and Pharmacology 2017年第1期5卷 1-4页

作者： Juliana Ramos chaves filipe Rocha da Silva Lucas Ivanilson Guedes Henriques Silva Thiago Farias Camara Luis Eduardo Wemeck de Carvalho Jonathan Souza Sarraf Oncologica Brasil--Education and Research Belem-PA 66053-000 Brazil Mecicine Faculty Universidade do Estado do Para Belem-PA 66087-670 Brazil Medicine Faculty Centro Universitario do Estado do Para Belem-PA 66613-903 Brazil Medicine Faculty Universidade Federal do Para Belem-PA 66075-110 Brazil

Melanoma is a malignant neoplasm that affects the melanocytes. Its treatment is based on cancer staging. In immunotherapy, it can be pointed out the ipilimumab, used in the systemic therapy for unresectable and/or metastatic melanoma in the first or the second line treatment with increased survival. However, limiting toxicity and the low complete response discourage its use in the elderly patients. The aim of this study is to report the case of an 83-year-old man, white, with scalp melanoma measuring 3.5 cm in its major axis. After two resections was verified that the deep margin was involved, making the lesions unresectable. The evaluation of distant metastasis, by skull, chest and abdomen CT-scan （computed tomography-scan）, was performed and did not detect the presence of any metastatic loci. The patient underwent the first cycle of chemotherapy with DTIC （dacarbazine） protocol. After the first cycle, the medication was discontinued due to significant myelotoxicity and Grade 3 thrombocytopenia. Underwent second line treatment with ipilimumab by four cycles. After this, the patient follow with complete local response, asymptomatic, with no signs of local recurrence or distant metastasis site, and no limiting toxicity during and after a year of treatment with ipilimumab. Thus, it is possible to suggest that the use of ipilimumab isolatedly as a second line treatment may have a good response even in elderly patients.

关键词： Scalp melanoma ipilimumab elderly patients.

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Molecular Cell Biology 2022年第6期14卷 68-71页

作者： Otávio Augusto chaves Carolina Q.Sacramento Natalia Fintelman-Rodrigues Jairo Ramos Temerozo filipe Pereira-Dutra Daniella M.Mizurini Robson Q.Monteiro Leonardo Vazquez Patricia T.Bozza Hugo Caire Castro-Faria-Neto Thiago Moreno L.Souza Laboratory of Immunopharmacology Oswaldo Cruz Institute(IOC)Oswaldo Cruz Foundation(Fiocruz)Rio de JaneiroRJ21040-900Brazil National Institute for Science and Technology on Innovation on Neglected Diseases(INCT/IDN) Center for Technological Development in Health(CDTS)Oswaldo Cruz Foundation(Fiocruz)Rio de JaneiroRJ21040-900Brazil National Institute for Science and Technology on Neuroimmunomodulation(INCT/NIM) Oswaldo Cruz Institute(IOC)Oswaldo Cruz Foundation(Fiocruz)Rio de JaneiroRJ21040-900Brazil Laboratory on Thymus Research Oswaldo Cruz Institute(IOC)Oswaldo Cruz Foundation(Fiocruz)Rio de JaneiroRJ21040-900Brazil Institute of Medical Biochemistry Leopoldo de Meis Federal University of Rio de Janeiro(UFRJ)Rio de JaneiroRJ21941-590Brazil

Dear Editor,The severe coronavirus disease 2019(COVID-19)is associated with ***,such as low-molecular-weight heparin,warfarin,thrombin inhibitors,and factor Xa(FXa)inhibitors,are thus recommended by the American Society of Hematology and National Institutes of Health for COVID-19 patients(Wenzler et al.,2020;Adam et al.,2021).Clinical trials with anticoagulants have shown the increased survival of critically ill COVID-19 patients under non-invasive and invasive ventilatory assistance(Wenzler et al.,2020;Adam et al.,2021),along with decreased consumption of platelets and clotting factors and a reduced risk of hemorrhage(Adam et al.,2021).Among the anti-clotting agents,early use of orally available FXa and thrombin inhibitors(Chowdhury et al.,2020;Rentsch et al.,2021)prevented high levels of D-dimer,which is the final product from the clotting/fibrinolysis cascade and is directly implicated with severe COVID-19(Rentsch et al.,2021).

关键词： al. Clinical heparin

螺内酯与可乐定作为难治性高血压第4种治疗药物的比较:难治性高血压的最佳治疗随机研究

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华高血压杂志 2018年第3期26卷 299-299页

作者： Krieger EM Drager LF Giorgi DMA Pereira AC Barreto-Filho JAS Nogueira AR Mill JG Lotufo PA Amodeo C Batista MC Bodanese LC Carvalho ACC Castro I chaves H Costa EAS Feitosa GS Franco RJS Fuchs FD Guimarāes AC Jardim PC Machado CA Magalhāes ME Mion D Jr Nascimento RM nobre F Nóbrega AC Ribeiro ALP Rodrigues-Sobrinho CR Sanjuliani AF Teixeira MDCB Krieger JE ReHOT Investigators 赵狄练桂丽

该研究旨在通过一个多中心随机试验对作为难治性高血压患者的第4种治疗药物的螺内酯与可乐定进行比较。采用药丸计数评估药物治疗依从性。难治性高血压患者（定义为包括1种利尿剂在内的3种药物治疗12周,诊室及动态血压监测血压仍未控制... 详细信息

该研究旨在通过一个多中心随机试验对作为难治性高血压患者的第4种治疗药物的螺内酯与可乐定进行比较。采用药丸计数评估药物治疗依从性。难治性高血压患者（定义为包括1种利尿剂在内的3种药物治疗12周,诊室及动态血压监测血压仍未控制）随机给予螺内酯（12.5～50 mg/d）或可乐定（0.1～0．3mg，2次／d）继续治疗12周。

关键词：难治性高血压随机研究治疗药物可乐定螺内酯最佳治疗药物治疗依从性多中心随机试验